About this source
- Kind
- Research
- Design
- Human clinical trial
- Population
- GAD/neurasthenia patients
- Sample size
- 62 (30 Selank, 32 medazepam)
- Primary or secondary
- primary
- Peer review
- peer reviewed
- Retraction status
- None known
- Date checked
- 14 August 2026
Limitations
Active-comparator trial, not placebo-controlled; single trial. Adverse-event data have not been checked against the full primary text.
Cited in
Anxiety trial versus medazepam
Selank · Research finding
LimitedNo adverse-event data identified
Selank · Safety finding
Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.